Oral roxadustat three times weekly in ESA‐naïve and ESA‐converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 …

T Akizawa, M Ueno, T Shiga… - … Apheresis and Dialysis, 2020 - Wiley Online Library
Roxadustat is a hypoxia‐inducible factor prolyl hydroxylase inhibitor approved in China for
anemia of dialysis‐dependent chronic kidney disease (CKD). Japanese hemodialysis …
被引用次数：59 相关文章

Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 …

T Akizawa, M Ueno, T Shiga… - Therapeutic Apheresis and …, 2020 - europepmc.org
Roxadustat is a hypoxia‐inducible factor prolyl hydroxylase inhibitor approved in China for
anemia of dialysis‐dependent chronic kidney disease (CKD). Japanese hemodialysis …

Oral roxadustat three times weekly in ESA‐naïve and ESA‐converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 …

T Akizawa, M Ueno, T Shiga, M Reusch - Therapeutic Apheresis and …, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Roxadustat is a hypoxia‐inducible factor prolyl
hydroxylase inhibitor approved in China for anemia of dialysis‐dependent chronic kidney …

Oral roxadustat three times weekly in ESA‐naïve and ESA‐converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 …

T Akizawa, M Ueno, T Shiga… - Therapeutic Apheresis & …, 2020 - search.ebscohost.com
Roxadustat is a hypoxia‐inducible factor prolyl hydroxylase inhibitor approved in China for
anemia of dialysis‐dependent chronic kidney disease (CKD). Japanese hemodialysis …
[HTML] nih.gov

[HTML][HTML] Oral roxadustat three times weekly in ESA‐naïve and ESA‐converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase …

T Akizawa, M Ueno, T Shiga… - Therapeutic Apheresis and …, 2020 - ncbi.nlm.nih.gov
Roxadustat is a hypoxia‐inducible factor prolyl hydroxylase inhibitor approved in China for
anemia of dialysis‐dependent chronic kidney disease (CKD). Japanese hemodialysis …

Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 …

T Akizawa, M Ueno, T Shiga… - … apheresis and dialysis …, 2020 - pubmed.ncbi.nlm.nih.gov
Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor approved in China for
anemia of dialysis-dependent chronic kidney disease (CKD). Japanese hemodialysis …